The treatment outcomes and the use of adjuvant therapies in breastcancer patients with severe co-morbidities

Collection with item attached
2017
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/486154.do
DOI
10.1371/journal.pone.0173721
Title
The treatment outcomes and the use of adjuvant therapies in breastcancer patients with severe co-morbidities
Description
This work was supported by the Basic Science Research Program throughthe National Research Foundation of Korea (NRF) funded by the Ministryof Education, Science and Technology (2015R1D1A1A02061904), by the grantfrom the National R&D Program for Cancer Control, Ministry for Healthand Welfare, Republic of Korea (A1520250), and by the grant of the KoreaHealth Industry Development Institute (KHIDI), funded by the Ministry ofHealth & Welfare, Republic of Korea (H114C1277 and HI13C2148). Thefunders had no role in study design, data collection and analysis,decision to publish, or preparation of the manuscript.
abstract
Purpose
Studies have suggested a potential role of patient's co-morbidity in determining the survival outcomes of breast cancer. In this study, we examined the long-term oncologic outcomes in breast cancer patients who underwent curative surgery according to their pre-existing comorbid conditions and analyzed the association between the co-morbidity and the use of adjuvant therapies.
Methods
The medical records of 2,501 patients who underwent surgery for primary breast cancer from June 2006 to June 2010 were reviewed retrospectively. The patients were classified into three groups according to preoperative ASA status determined by the anesthesiologists. Clinico-pathologic characteristics and survival outcomes of the patients were compared among the different co-morbidity groups.
Results
There were 1,792 (71.6%), 665 (26.6%), and 44 (1.8%) patients in ASA I, II, and III, respectively. Total 95 (3.8%) deaths and 269 (10.8%) recurrences (loco-regional and distant) occurred during the median follow-up period of 71 months. Patients with high comorbidity showed significantly higher rate of deaths (51 (2.8%), 38 (5.7%) and 6 (13.6%) deaths in ASA I, II and III group, respectively, p<0.001). The ASA 3 patients also showed significantly higher rate of breast cancer recurrence when compared to other groups (180 (10.0%), 80 (12.0%) and 9 (20.5%) in ASA I, II, and III, respectively, p = 0.041). Significantly fewer patients in the high co-morbidity group received adjuvant therapies (77 (4.3%), 44 (6.6%) and 8 (18.2%) in ASA I, II, and III, respectively, p<0.001). The increased recurrence of breast cancer in the high morbidity group was mostly seen in patients who did not receive adjuvant therapies. The incidence of serious adverse effect during the adjuvant therapy did not differ according to the co-morbidity conditions.
Conclusions
In this study, high comorbidity was related to increased risk of death and recurrence in breast cancer. The increased risk of recurrence in high co-m
provenance
Made available in Cube on 2018-09-28T15:59:57Z (GMT). No. of bitstreams: 0
language
English
author
Han, Jaihong
Lee, Han-Byoel
Lee, Eun-Shin
Kang, Young Joon
Kim, Yumi
Choi, Jihye
Rhu, Jiyoung
Shin, Hee-Chul
Han, Wonshik
Noh, Dong-Young
Moon, Hyeong-Gon
orcid
Moon, Hyeong-Gon/0000-0002-9981-0286
accessioned
2018-09-28T15:59:57Z
available
2018-09-28T15:59:57Z
issued
2017
citation
PLOS ONE(12): 3
issn
1932-6203
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/486154.do
Funder
보건복지부
Funding Program
첨단의료기술개발
Project ID
1465024812
Jurisdiction
Rep.of Korea
Project Name
Development of hormone receptor positive breast cancer personalized medical system using PDX model
rights
openAccess
type
article


Files in This Item

There are no attached files.